MX2016002408A - Metodos para el tratamiento de trastornos oticos pediatricos. - Google Patents

Metodos para el tratamiento de trastornos oticos pediatricos.

Info

Publication number
MX2016002408A
MX2016002408A MX2016002408A MX2016002408A MX2016002408A MX 2016002408 A MX2016002408 A MX 2016002408A MX 2016002408 A MX2016002408 A MX 2016002408A MX 2016002408 A MX2016002408 A MX 2016002408A MX 2016002408 A MX2016002408 A MX 2016002408A
Authority
MX
Mexico
Prior art keywords
treatment
otic disorders
pediatric
pediatric otic
compositions
Prior art date
Application number
MX2016002408A
Other languages
English (en)
Inventor
Piu Fabrice
Ye Qiang
A Dellamary Luis
Lebel Carl
Original Assignee
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otonomy Inc filed Critical Otonomy Inc
Publication of MX2016002408A publication Critical patent/MX2016002408A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen aquí métodos para el tratamiento de enfermedades o afecciones óticas pediátricas con composiciones y formulaciones de agentes antimicrobianos administradas localmente a un individuo afligido con una enfermedad o afección ótica, a través de aplicación directa de estas composiciones y formulaciones sobre o a través de perfusión en la estructura(s) de oído objetivo.
MX2016002408A 2013-08-27 2014-08-26 Metodos para el tratamiento de trastornos oticos pediatricos. MX2016002408A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361870318P 2013-08-27 2013-08-27
US201361914904P 2013-12-11 2013-12-11
PCT/US2014/052754 WO2015031393A1 (en) 2013-08-27 2014-08-26 Treatment of pediatric otic disorders

Publications (1)

Publication Number Publication Date
MX2016002408A true MX2016002408A (es) 2016-10-28

Family

ID=52587275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002408A MX2016002408A (es) 2013-08-27 2014-08-26 Metodos para el tratamiento de trastornos oticos pediatricos.

Country Status (10)

Country Link
US (2) US9486405B2 (es)
EP (1) EP3038707A4 (es)
JP (1) JP2016534121A (es)
KR (1) KR20160047490A (es)
CN (1) CN105682742A (es)
AU (1) AU2014311358A1 (es)
CA (1) CA2921816A1 (es)
EA (1) EA201690323A1 (es)
MX (1) MX2016002408A (es)
WO (1) WO2015031393A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
JP6297180B2 (ja) 2014-07-03 2018-03-20 オトノミ—，インク． シプロフロキサシン組成物の滅菌
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
EP3518929A4 (en) * 2016-09-30 2020-05-06 Otonomy, Inc. OTIC GEL FORMULATIONS FOR THE TREATMENT OF OTITIS MEDIA
EP3737233A4 (en) * 2018-01-09 2021-10-13 Otonomy, Inc. GROWTH FACTOR FORMULATIONS FOR THE EAR
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
EP3962533A4 (en) 2019-04-30 2023-01-25 The Medical College of Wisconsin, Inc. PLATFORM FOR THROAT ADMINISTRATION AND USES THEREOF

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
JPH01258620A (ja) 1988-04-08 1989-10-16 Dai Ichi Seiyaku Co Ltd 耳疾患用局所製剤
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5292516A (en) 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
IT1251151B (it) 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
JP3696265B2 (ja) 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
DE69524398T2 (de) 1994-04-08 2002-07-18 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
CA2228118A1 (en) 1995-07-28 1997-02-13 Focal, Inc. Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatments agents
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6045528A (en) 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
BR9814615A (pt) 1997-10-22 2001-10-16 Jens Ponikau Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
JP2001526246A (ja) 1997-12-23 2001-12-18 アライアンス・ファーマスーティカル・コーポレイション 薬剤送達及び／又は癒着防止のための方法及び組成物
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
WO2000050005A1 (en) 1999-02-24 2000-08-31 Dong Wha Pharm. Ind. Co., Ltd Liquid suppository composition of diclofenac sodium
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
ATE252887T1 (de) 1999-09-24 2003-11-15 Alcon Inc Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6632423B2 (en) 2000-03-14 2003-10-14 Alcon, Inc. Viscoelastics for use in middle ear surgery
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US20040022853A1 (en) 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
TWI324925B (en) 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
MXPA04002576A (es) 2001-09-21 2004-06-18 Alcon Inc Metodo para tratar infecciones del oido medio.
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10162593A1 (de) 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
WO2003071986A2 (en) 2002-02-22 2003-09-04 Control Delivery Systems, Inc. Method for treating otic disorders
US20060013858A1 (en) 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US20040101506A1 (en) 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
US7700086B2 (en) 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CA2568028A1 (en) 2004-05-24 2005-12-08 Auris Medical, Llc. Combined otic aspirator and medication dispenser
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
US20060046970A1 (en) 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
BRPI0514898A (pt) 2004-09-03 2008-06-24 Piedmont Pharmaceuticals Llc métodos para tratamento e prevenção transmembrana da otite média
JP2006111585A (ja) 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
WO2006079055A2 (en) 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2006099325A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
WO2006102964A2 (en) 2005-03-29 2006-10-05 Evonik Röhm Gmbh Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
KR101041843B1 (ko) 2005-07-30 2011-06-17 삼성엘이디 주식회사 질화물계 화합물 반도체 발광소자 및 그 제조방법
WO2007025142A2 (en) 2005-08-26 2007-03-01 Ladd Byron S Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
EA200800950A1 (ru) 2005-09-26 2008-08-29 ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
ZA200803367B (en) 2005-09-26 2009-09-30 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear
EA017264B1 (ru) 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP2032124A1 (en) 2006-06-27 2009-03-11 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2094169A4 (en) 2006-12-11 2016-05-04 Pluromed Inc HEMOSTASIS OF PERFUSED ORGANS
EP2150244A1 (en) 2007-04-23 2010-02-10 House Ear Institute Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
RU2499592C2 (ru) 2008-04-21 2013-11-27 Отономи, Инк. Фармацевтическая композиция для лечения ушных заболеваний
MY161021A (en) 2008-05-14 2017-03-31 Otonomy Inc Controlled release corticosteroid and methods for the treatment of otic disorders
US8822410B2 (en) 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US20100016218A1 (en) 2008-07-14 2010-01-21 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN104352429B (zh) 2008-07-21 2018-05-18 奥德纳米有限公司 用于治疗耳部病症的受控释放抗微生物组合物和方法
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN101664381A (zh) 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛***炎的原位凝胶缓释制剂的制备方法
EP3508197A1 (en) * 2009-10-21 2019-07-10 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.

Also Published As

Publication number Publication date
WO2015031393A1 (en) 2015-03-05
US20170027930A1 (en) 2017-02-02
CA2921816A1 (en) 2015-03-05
US9486405B2 (en) 2016-11-08
AU2014311358A1 (en) 2016-04-07
EP3038707A1 (en) 2016-07-06
JP2016534121A (ja) 2016-11-04
EA201690323A1 (ru) 2016-07-29
EP3038707A4 (en) 2017-03-01
CN105682742A (zh) 2016-06-15
US20150290124A1 (en) 2015-10-15
KR20160047490A (ko) 2016-05-02

Similar Documents

Publication Publication Date Title
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
WO2010011609A3 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2011050206A3 (en) Compositions and methods for the treatment of sinonasal disorders
WO2010008995A3 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2010011605A3 (en) Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
WO2010011466A3 (en) Controlled-release cns modulating compositions and methods for the treatment of otic disorders
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2020012924A (es) Terapias combinadas de coenzima q10 para el tratamiento de cancer.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2010074992A3 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.